Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse event
Genetic medicine specialist Lexeo Therapeutics is the latest biotech to line up an initial public offering (IPO), aiming to raise around $100 million from the transaction.
Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca, which includes $245 million in near-term financial com
Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy has failed to meet its primary objective in a phase 3 trial, but the company says it will file to extend
Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial.
Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.